Fusen Pharmaceutical Co., Ltd. (HK:1652)
:1652
Top Page
Fusen Pharmaceutical Co., Ltd.
(1652)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.72
▼(-10.50% Downside)
Action:ReiteratedDate:11/04/25
The overall stock score is primarily impacted by significant financial challenges, including declining revenues, profitability issues, and liquidity risks. While technical indicators show some positive trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a low overall score.
Positive Factors
Diversified revenue streams
Multiple durable revenue channels — prescription drugs, OTC products, collaborations and licensing — reduce single-product dependence and smooth cash flow volatility. Licensing and partnerships provide non-linear revenue upside and recurring royalties that support long-term business resilience.
Negative Factors
Sharp revenue contraction
A roughly 43% revenue decline is a structurally negative signal: it erodes scale advantages, reduces the ability to fund R&D and commercialization, and pressures pricing power. Sustained revenue contraction impairs long-term competitiveness and recovery runway.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
Multiple durable revenue channels — prescription drugs, OTC products, collaborations and licensing — reduce single-product dependence and smooth cash flow volatility. Licensing and partnerships provide non-linear revenue upside and recurring royalties that support long-term business resilience.
Read all positive factors
Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$926.38M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth-43.46%
EPS Growth-96.48%
CountryHK
Employees1,131
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding739,301,000
10 Day Avg. Volume642,000
30 Day Avg. Volume1,233,253
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.50
Price to Sales (P/S)1.71
P/FCF Ratio9.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuangh...
How the Company Makes Money
Fusen Pharmaceutical generates revenue through multiple key streams, including the sale of prescription medications and over-the-counter products. The company profits from its proprietary drug formulations, which are marketed through a combination...
Fusen Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
55
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 240.99M | 326.03M | 565.61M | 491.76M | 385.66M | 486.85M |
| Gross Profit | 99.75M | 162.64M | 299.51M | 225.02M | 211.13M | 266.07M |
| EBITDA | -17.97M | -39.07M | 18.93M | 49.90M | 55.82M | 110.30M |
| Net Income | -174.98M | -188.78M | -36.28M | -34.65M | 16.64M | 70.13M |
Balance Sheet | ||||||
| Total Assets | 1.23B | 1.24B | 1.34B | 1.35B | 1.24B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 75.99M | 21.06M | 34.85M | 128.11M | 81.70M | 312.53M |
| Total Debt | 364.67M | 383.69M | 344.12M | 228.38M | 240.69M | 198.50M |
| Total Liabilities | 887.44M | 869.80M | 781.52M | 737.38M | 582.39M | 583.10M |
| Stockholders Equity | 346.55M | 369.67M | 563.52M | 614.17M | 658.17M | 659.44M |
Cash Flow | ||||||
| Free Cash Flow | 121.56M | 57.43M | -161.84M | 86.63M | -62.37M | 94.56M |
| Operating Cash Flow | 171.26M | 133.73M | -73.33M | 110.49M | 47.77M | 153.21M |
| Investing Cash Flow | -98.24M | -163.42M | -108.32M | -13.13M | -282.98M | -68.20M |
| Financing Cash Flow | -1.00M | 15.99M | 88.50M | -51.77M | 20.53M | -116.33M |
Fusen Pharmaceutical Co., Ltd. Technical Analysis
Positive
0.80
Price Trends
1.00
Positive
0.90
Positive
0.71
Positive
Market Momentum
0.07
Positive
56.41
Neutral
43.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1652, the sentiment is Positive. The current price of 0.8 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.00, and above the 200-day MA of 0.71, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 56.41 is Neutral, neither overbought nor oversold. The STOCH value of 43.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1652.
Fusen Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$677.60M | 24.59 | 1.57% | 9.43% | -1.99% | -81.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$926.38M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$683.28M | -3.17 | 20.98% | ― | ― | ― | |
48 Neutral | HK$177.84M | -38.07 | -8.95% | ― | 2.54% | 33.33% | |
44 Neutral | HK$208.55M | -3.96 | -11.18% | ― | -19.28% | -42.27% | |
42 Neutral | HK$163.16M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.26
1.02
425.00%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.07
-42.26%
HK:1011
China NT Pharma Group Co., Ltd.
0.72
0.49
213.04%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.20
-39.00%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.80
0.00
0.00%
HK:8622
Huakang Biomedical Holdings Company Limited
0.35
0.06
23.21%
Fusen Pharmaceutical Co., Ltd. Corporate Events
Fusen Pharmaceutical Wins China Approval for New Phosphate Injection
Dec 29, 2025
Fusen Pharmaceutical said its wholly owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology has received Chinese regulatory approval to market Compound Potassium Hydrogen Phosphate Injection, a Class B reimbursable drug used as a pare...
Fusen Pharmaceutical Replaces KPMG With CCTH as Auditor to Cut Costs
Dec 24, 2025
Fusen Pharmaceutical Company Limited has announced a change of auditor, with KPMG resigning effective 24 December 2025 after the two sides failed to agree on the audit fee for the Group’s 2025 consolidated financial statements. The board and...
Fusen Pharmaceutical Gains Approval for Nicardipine Hydrochloride Injection
Dec 12, 2025
Fusen Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration of the PRC for the consistency evaluation of its Nicardipine Hydrochloride Injection. This product, used for emergency management of perioperati...
Fusen Pharmaceutical’s New Hypertension Drug Gains Approval in China
Nov 14, 2025
Fusen Pharmaceutical Co., Ltd. announced that its subsidiary, Jiaheng Pharmaceutical Technology, has received approval from the National Medical Products Administration of the PRC to market ‘Measartan Potassium Tablets’ for treating pr...
Fusen Pharmaceutical’s Enzalutamide Soft Capsule Approved for Prostate Cancer Treatment in China
Oct 30, 2025
Fusen Pharmaceutical Co., Ltd. announced the approval of its ‘Enzalutamide Soft Capsule’ for marketing in China, targeting non-metastatic and metastatic castration-resistant prostate cancer. This product, developed by its subsidiary Ji...
Fusen Pharmaceutical’s Product Selected in National Procurement
Oct 30, 2025
Fusen Pharmaceutical Co., Ltd. announced that its Metformin Empagliflozin Tablets were selected in the eleventh batch of China’s National Centralised Medicines Procurement. This selection is a significant development for the company, potenti...
Fusen Pharmaceutical Announces Disposal of Equity Interests
Oct 27, 2025
Fusen Pharmaceutical Co., Ltd. announced a supplemental disclosure regarding the disposal of its entire equity interests in Henan Fusen Intelligent Energy Conservation Technology Co., Ltd. The consideration for this transaction was determined thro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.